title: A prospective, randomized comparison of promus everolimus-eluting and TAXUS Liberte paclitaxel-eluting stent systems in patients with coronary artery disease eligible for percutaneous coronary intervention: the PROMISE study.
abstract: We aimed comparing two-year clinical outcomes of the Everolimus-Eluting Promus and Paclitaxel-Eluting TAXUS Liberte stents used in routine clinical practice. Patients with objective evidence of ischemia and coronary artery disease eligible for PCI were prospectively randomized to everolimus-eluting stent (EES) or paclitaxel-eluting stent (PES) groups. The primary end-point was ischemia-driven target vessel revascularization (TVR) at 2 yr after intervention, and the secondary end-point was a major adverse cardiac event (MACE), such as death, myocardial infarction (MI), target lesion revascularization (TLR), TVR or stent thrombosis. A total of 850 patients with 1,039 lesions was randomized to the EES (n=425) and PES (n=425) groups. Ischemic-driven TVR at 2 yr was 3.8% in the PES and 1.2% in the EES group (P for non-inferiority=0.021). MACE rates were significantly different; 5.6% in PES and 2.5% in EES (P = 0.027). Rates of MI (0.8% in PES vs 0.2% in EES, P = 0.308), all deaths (1.5% in PES vs 1.2% in EES, P = 0.739) and stent thrombosis (0.3% in PES vs 0.7% in EES, P = 0.325) were similar. The clinical outcomes of EES are superior to PES, mainly due to a reduction in the rate of ischemia-driven TVR.
authors.affiliation: Division of Cardiology, Yeungnam University Medical Center, Daegu, Korea.
authors.forename: Ung
authors.initials: U
authors.lastname: Kim
authors.forename: Chan-Hee
authors.initials: CH
authors.lastname: Lee
authors.forename: Jung-Hwan
authors.initials: JH
authors.lastname: Jo
authors.forename: Hyun-Wook
authors.initials: HW
authors.lastname: Lee
authors.forename: Yoon-Jung
authors.initials: YJ
authors.lastname: Choi
authors.forename: Jang-Won
authors.initials: JW
authors.lastname: Son
authors.forename: Sang-Hee
authors.initials: SH
authors.lastname: Lee
authors.forename: Jong-Seon
authors.initials: JS
authors.lastname: Park
authors.forename: Dong-Gu
authors.initials: DG
authors.lastname: Shin
authors.forename: Young-Jo
authors.initials: YJ
authors.lastname: Kim
authors.forename: Myung-Ho
authors.initials: MH
authors.lastname: Jeong
authors.forename: Myung-Chan
authors.initials: MC
authors.lastname: Cho
authors.forename: Jang-Ho
authors.initials: JH
authors.lastname: Bae
authors.forename: Jae-Hwan
authors.initials: JH
authors.lastname: Lee
authors.forename: Tae-Soo
authors.initials: TS
authors.lastname: Kang
authors.forename: Kyung-Tae
authors.initials: KT
authors.lastname: Jung
authors.forename: Kyung-Ho
authors.initials: KH
authors.lastname: Jung
authors.forename: Seung-Wook
authors.initials: SW
authors.lastname: Lee
authors.forename: Jang-Hyun
authors.initials: JH
authors.lastname: Cho
authors.forename: Won
authors.initials: W
authors.lastname: Kim
authors.forename: Seung-Ho
authors.initials: SH
authors.lastname: Hur
authors.forename: Ki-Sik
authors.initials: KS
authors.lastname: Kim
authors.forename: Heon-Sik
authors.initials: HS
authors.lastname: Park
authors.forename: Moo-Hyun
authors.initials: MH
authors.lastname: Kim
authors.forename: Jin-Yong
authors.initials: JY
authors.lastname: Hwang
authors.forename: Doo-Il
authors.initials: DI
authors.lastname: Kim
authors.forename: Tae-Ik
authors.initials: TI
authors.lastname: Kim
mesh_terms: D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage / Q000627:therapeutic use; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000401:mortality; D023903:Coronary Restenosis / Q000517:prevention & control; D054855:Drug-Eluting Stents; D000068338:Everolimus; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D011446:Prospective Studies; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013927:Thrombosis; D016896:Treatment Outcome
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D007166:Immunosuppressive Agents; D000068338:Everolimus; D017239:Paclitaxel; D020123:Sirolimus
keywords: Everolimus-Eluting Stent; Paclitaxel-Eluting Stent